

CORRIGENDUM

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

M. E. Pavel, E. Baudin, K. E. Öberg, J. D. Hainsworth, M. Voi, N. Rouyrre, M. Peeters, D. J. Gross & J. C. Yao

Ann Oncol 2017; 28(7): 1569–1575 (doi: 10.1093/annonc/mdx193)

The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”